Clinical evaluation of simvastatin on prothrombotic state in OSAS pa-tients with hypertension without hyperlipemia
- VernacularTitle:辛伐他汀改善OSAS并高血压血脂正常患者血栓前状态的临床评价
- Author:
Ranran LIU
1
;
Keji CHENG
Author Information
1. 抚顺矿务局总医院药剂科
- Keywords:
Obstructive Sleep apnea Syndrome;
Hypertension;
Simvastatin;
Prothrombotic state
- From:
China Modern Doctor
2015;(13):74-76,80
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of simvastatin on prothrombotic state in OSAS patients with hypertension without hyperlipemia. Methods Eighty OSAS patients with hypertension without hyperlipemia were enrolled from Jan-uary 2011 to June 2014,and randomly divided into simvastatin group(40 cases)and conventional group(40 cases)(oral taken simvastatin or placeb once every night in addition of routine antihypertensive drugs).Forty healthy subjects were also recruited as control.All cases were followed up for eight weeks. Serum holesterol,nitric oxide(NO),emdothelin-1(ET-1),von Willebrand-factor(vWF) and tissue-type plasminogen activator(t-PA) levels were determined in each case before and after eight weeks orsuvastatin medication. Results Before treatment NO,t-PA levels in simvastatin group and conventional group were lower than the healthy group,ET-1, vWF levels were higher than those of control group,the differences were statistically significant(P<0.05). After treatment NO,t-PA levels in simvastatin group and conventional group increased compared with before treatment,but simvastatin group increased more significantly,ET-1,vWF levels in simvastatin group and conventional group were lower than before treatment,but simvastatin group they were more significantly lower, with statistically significant difference (P<0.05). Conclusion In patients of OSAS pa-tients with hypertension without hyper-lipemia,simvastatin can increase plasma NO,t-PA concentration and decrease ET-1,vWF concentration and thus to improve the prothrombotic status.
